Myth: “All Probiotics Are the Same”

Myth Busting · July 29, 2026 · 6 min read

To the average dog owner scanning a supplement shelf, probiotics look interchangeable. They come in similar bottles, promise similar benefits (“supports digestive health!”), and list similar-sounding Latin names. The reasonable conclusion: they are basically the same product with different labels and price tags.

This conclusion is wrong. It is also potentially harmful, because it leads owners to choose based on price, packaging, or CFU count rather than biological relevance. The truth is that probiotic strains differ as dramatically as pharmaceutical drugs within the same therapeutic class. The mechanism, the evidence, and the clinical application are strain-specific.

The Taxonomy Problem: Genus, Species, Strain

Probiotic nomenclature follows a three-level hierarchy:

• Genus: Lactobacillus, Bifidobacterium, Enterococcus, Bacillus, Saccharomyces
• Species: L. acidophilus, L. rhamnosus, B. animalis, E. faecium
• Strain: L. rhamnosus GG, B. animalis subsp. lactis BB-12, E. faecium SF68

The strain designation — the alphanumeric suffix — is where biological identity lives. Two strains of Lactobacillus rhamnosus can share 99% genomic similarity yet differ in critical functional genes: adhesion factors, bacteriocin production, antibiotic resistance profiles, and immune-stimulatory capacity.

An analogy: all beta-blockers share a mechanism class. But propranolol, atenolol, and carvedilol have different selectivity, different pharmacokinetics, and different approved indications. You would not substitute one for another without clinical justification. The same logic applies to probiotic strains.

Different Strains, Different Mechanisms

Consider four well-characterized organisms used in canine or veterinary-context products:

Enterococcus faecium SF68

• Primary mechanism: Competitive exclusion of pathogenic Enterobacteriaceae; production of bacteriocins active against Clostridium perfringens and Salmonella spp.
• Immune profile: Modest immunomodulation; primarily acts through direct microbial competition.
• Canine evidence: Multiple RCTs demonstrating reduced duration of acute diarrhea and reduced fecal Enterococcus/Streptococcus pathogen loads.
• Best application: Acute GI disturbance, antibiotic-associated diarrhea.

Saccharomyces boulardii CNCM I-745

• Primary mechanism: Secretion of proteases that degrade Clostridioides difficile toxins A and B; trophic effects on enterocytes via polyamine production.
• Immune profile: Anti-inflammatory; reduces IL-8 and NF-κB activation in intestinal epithelium.
• Canine evidence: Limited but growing; demonstrated benefit in canine parvovirus recovery and chronic enteropathy adjunct therapy.
• Best application: Toxin-mediated diarrhea, antibiotic-associated colitis.

Lactobacillus acidophilus NCFM

• Primary mechanism: Adhesion to intestinal mucosa via mucus-binding proteins; production of lactic acid and acidolin (a bacteriocin); competitive exclusion of E. coli and Salmonella.
• Immune profile: Stimulates secretory IgA production; modulates dendritic cell cytokine profiles toward Th1 balance.
• Canine evidence: Primarily extrapolated from human trials; limited direct canine RCTs.
• Best application: General digestive support, immune priming.

Bacillus subtilis DE111

• Primary mechanism: Spore-forming; survives gastric acid without encapsulation. Produces surfactin and iturin lipopeptides with broad antimicrobial activity. Germinates in the small intestine and produces enzymes (protease, amylase, lipase) aiding digestion.
• Immune profile: Stimulates innate immune signaling via flagellin-TLR5 interaction during germination.
• Canine evidence: Emerging; demonstrated improved fecal consistency and reduced pathogenic Clostridium spp. in pilot canine trials.
• Best application: Digestive enzyme support, heat-stable formulations.

These four organisms share the label “probiotic.” Their mechanisms, evidence bases, stability profiles, and clinical applications are fundamentally different. Treating them as interchangeable is biologically incoherent.

The Evidence Base Is Strain-Specific

This is the point most often missed in consumer marketing: clinical trial results apply to the specific strain tested, not to the species or genus.

If a trial demonstrates that Lactobacillus rhamnosus GG reduces antibiotic-associated diarrhea by 42%, that finding cannot be extrapolated to L. rhamnosus HN001, or to any other L. rhamnosus strain, without independent confirmation. The genomes differ. The surface proteins differ. The metabolite profiles differ.

A 2021 meta-analysis in Beneficial Microbes reviewed 89 probiotic trials across human and animal species. Only 23% reported strain-level identification. Of those, only 31% used strains with prior published evidence in the target species. The remaining 69% extrapolated from related strains or from human data — an approach with unknown validity.

Why Multi-Strain Blends Obscure the Problem

Many commercial canine probiotics contain 5, 10, or 15 strains in a single formula. This creates an illusion of comprehensiveness: “covers all bases.” In practice, multi-strain blends often:

• Lack co-culture compatibility data. Some strains produce bacteriocins that inhibit other strains in the blend. Without compatibility testing, you may be paying for organisms that kill each other in the capsule.
• Dilute individual strain doses. A “50 billion CFU, 10-strain” formula may deliver 5 billion per strain — potentially below the threshold demonstrated in single-strain trials.
• Obscure accountability. If the product works, which strain is responsible? If it fails, which strain was inadequate? Blends make it impossible to attribute outcomes.
• Rarely have blend-specific evidence. The strains may be individually studied, but the specific combination at the specific ratios in the specific delivery format is almost never tested as a unit.

This does not mean all multi-strain products are ineffective. Rationally designed combinations with compatibility data and blend-level trials exist. But they are the exception, not the rule.

Strain-Specific Safety Considerations

Safety also varies by strain:

• Antibiotic resistance genes: Some Enterococcus strains carry transferable vancomycin resistance (vanA, vanB). E. faecium SF68 has been specifically screened and confirmed free of transferable resistance. Generic E. faecium without strain verification may not be.
• Biogenic amine production: Certain Lactobacillus strains produce histamine or tyramine, which can exacerbate symptoms in sensitive individuals. Strain selection matters for dogs with mast cell disease or histamine intolerance.
• D-lactic acid production: Some strains produce D-lactate rather than L-lactate. In animals with short bowel syndrome or impaired D-lactate metabolism, this can contribute to metabolic acidosis.

These safety distinctions are invisible at the species level. They require strain-level characterization — genomic sequencing, phenotypic testing, and documented safety history.

How to Evaluate Strain Claims

1. Demand the strain designation. If the label says only “Lactobacillus acidophilus” without a strain suffix, the manufacturer is either using an uncharacterized strain or hiding behind genus-level language.
2. Ask for the deposition number. Characterized strains are deposited in culture collections (ATCC, DSMZ, CNCM, NCIMB). A deposition number (e.g., “ATCC 700396”) confirms the strain is identifiable and reproducible.
3. Look for strain-specific publications. Search PubMed for the exact strain name. If the only studies are in vitro or in a different species, note the extrapolation gap.
4. Check for genomic characterization. Leading strains have published whole-genome sequences. This confirms absence of virulence factors and transferable resistance genes.
5. Verify the strain matches the indication. A strain studied for diarrhea is not automatically useful for skin health, oral health, or anxiety. Match evidence to goal.

The Bottom Line

“Probiotic” is a category, not a product. Within that category exist thousands of strains with different genomes, different mechanisms, different evidence bases, and different safety profiles. Saying “all probiotics are the same” is like saying “all medications are the same” because they come in pill form.

The responsible approach: identify your dog’s specific health goal, find strains with published evidence for that goal in the target species, and choose products that identify their strains transparently and back them with verifiable data. The Latin name on the label is the beginning of due diligence, not the end.